Myocardial ischemic reperfusion induces de novo Nrf2 protein translation

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 9, 2014, Pages 1638-1647

  Xu, Beibei ^a   Zhang, Jack ^a   Strom, Joshua ^a   Lee, Sang ^a   Chen, Qin M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Cardiac protection; Ischemic stress; Protein translation; RNA binding

Indexed keywords

LA ANTIGEN; MESSENGER RNA; RIBONUCLEOPROTEIN; TRANSCRIPTION FACTOR NRF2;

5' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ARTICLE; HEART INFARCTION SIZE; HEART MUSCLE CELL; HEART MUSCLE REPERFUSION; IMMUNOPRECIPITATION; ISCHEMIC PRECONDITIONING; KNOCKOUT MOUSE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROCESSING; RIBOSOME; WESTERN BLOTTING; ANIMAL MODEL; ANIMAL TISSUE; BIOTINYLATION; CELL CULTURE; CELL ISOLATION; CONTROLLED STUDY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; MALE; RNA TRANSLATION; WILD TYPE;

CARDIAC PROTECTION; ISCHEMIC STRESS; PROTEIN TRANSLATION; RNA BINDING;

ANIMALS; BLOTTING, WESTERN; CELLS, CULTURED; HYDROGEN PEROXIDE; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCYTES, CARDIAC; NF-E2-RELATED FACTOR 2; OXIDANTS; OXIDATIVE STRESS; PROTEIN MODIFICATION, TRANSLATIONAL; RATS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMES; RNA, MESSENGER; RNA, SMALL INTERFERING; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC;

EID: 84903905294     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.06.002     Document Type: Article

References (62)

1. Jackson R.J., Hellen C.U., Pestova T.V. The mechanism of eukaryotic translation initiation and principles of its regulation. Nat. Rev. Mol. Cell Biol. 2010, 11:113-127.
2. Holcik M., Sonenberg N. Translational control in stress and apoptosis. Nat. Rev. Mol. Cell Biol. 2005, 6:318-327.
3. Yamasaki S., Anderson P. Reprogramming mRNA translation during stress. Curr. Opin. Cell Biol. 2008, 20:222-226.
4. Baird S.D., Turcotte M., Korneluk R.G., Holcik M. Searching for IRES. RNA 2006, 12:1755-1785.
5. Spriggs K.A., Bushell M., Mitchell S.A., Willis A.E. Internal ribosome entry segment-mediated translation during apoptosis: the role of IRES-trans-acting factors. Cell Death Differ. 2005, 12:585-591.
6. Lewis S.M., Holcik M. For IRES trans-acting factors, it is all about location. Oncogene 2008, 27:1033-1035.
7. Yang D.Q., Halaby M.J., Zhang Y. The identification of an internal ribosomal entry site in the 5'-untranslated region of p53 mRNA provides a novel mechanism for the regulation of its translation following DNA damage. Oncogene 2006, 25:4613-4619.
8. Sun J., Conn C.S., Han Y., Yeung V., Qian S.B. PI3K-mTORC1 attenuates stress response by inhibiting cap-independent Hsp70 translation. J. Biol. Chem. 2011, 286:6791-6800.
9. Damiano F., Alemanno S., Gnoni G.V., Siculella L. Translational control of the sterol-regulatory transcription factor SREBP-1 mRNA in response to serum starvation or ER stress is mediated by an internal ribosome entry site. Biochem. J. 2010, 429:603-612.
10. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74:1124-1136.
11. Shlafer M., Myers C.L., Adkins S. Mitochondrial hydrogen peroxide generation and activities of glutathione peroxidase and superoxide dismutase following global ischemia. J. Mol. Cell. Cardiol. 1987, 19:1195-1206.
12. Vandeplassche G., Hermans C., Thone F., Borgers M. Mitochondrial hydrogen peroxide generation by NADH-oxidase activity following regional myocardial ischemia in the dog. J. Mol. Cell. Cardiol. 1989, 21:383-392.
13. Grill H.P., Zweier J.L., Kuppusamy P., Weisfeldt M.L., Flaherty J.T. Direct measurement of myocardial free radical generation in an in vivo model: effects of postischemic reperfusion and treatment with human recombinant superoxide dismutase. J. Am. Coll. Cardiol. 1992, 20:1604-1611.
14. Zweier J.L., Talukder M.A. The role of oxidants and free radicals in reperfusion injury. Cardiovasc. Res. 2006, 70:181-190.
15. Diaz-Araya G., Nettle D., Castro P., Miranda F., Greig D., Campos X., Chiong M., Nazzal C., Corbalan R., Lavandero S. Oxidative stress after reperfusion with primary coronary angioplasty: lack of effect of glucose-insulin-potassium infusion. Crit. Care Med. 2002, 30:417-421.
16. Iuliano L., Pratico D., Greco C., Mangieri E., Scibilia G., FitzGerald G.A., Violi F. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J. Am. Coll. Cardiol. 2001, 37:76-80.
17. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
18. Yusuf S., Dagenais G., Pogue J., Bosch J., Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000, 342:154-160.
19. Keith M.E., Jeejeebhoy K.N., Langer A., Kurian R., Barr A., O'Kelly B., Sole M.J. A controlled clinical trial of vitamin E supplementation in patients with congestive heart failure. Am. J. Clin. Nutr. 2001, 73:219-224.
20. G.Heart Protection Study Collaborative MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:23-33.
21. Arad Y., Spadaro L.A., Roth M., Newstein D., Guerci A.D. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J. Am. Coll. Cardiol. 2005, 46:166-172.
22. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar G. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142:37-46.
23. Wang G., Hamid T., Keith R.J., Zhou G., Partridge C.R., Xiang X., Kingery J.R., Lewis R.K., Li Q., Rokosh D.G., Ford R., Spinale F.G., Riggs D.W., Srivastava S., Bhatnagar A., Bolli R., Prabhu S.D. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation 2010, 121:1912-1925.
24. Das D.K. Thioredoxin regulation of ischemic preconditioning. Antioxid. Redox Signal. 2004, 6:405-412.
25. Das D.K., Maulik N. Cardiac genomic response following preconditioning stimulus. Cardiovasc. Res. 2006, 70:254-263.
26. Nguyen T., Nioi P., Pickett C.B. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J. Biol. Chem. 2009, 284:13291-13295.
27. Kensler T.W., Wakabayashi N., Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 2007, 47:89-116.
28. Lee J.M., Calkins M.J., Chan K., Kan Y.W., Johnson J.A. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem. 2003, 278:12029-12038.
29. Malhotra D., Portales-Casamar E., Singh A., Srivastava S., Arenillas D., Happel C., Shyr C., Wakabayashi N., Kensler T.W., Wasserman W.W., Biswal S. Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res. 2010, 38:5718-5734.
30. Purdom-Dickinson S.E., Sheveleva E.V., Sun H., Chen Q.M. Translational control of Nrf2 protein in activation of antioxidant response element by oxidants. Mol. Pharm. 2007, 72:1074-1081.
31. Zhang J., Dinh T., Kapperler K., Chen Q. La autoantigen mediates oxidant induced de novo Nrf2 protein translation. Mol. Cell. Proteomics 2012, 11. (M111.015032).
32. Michael L.H., Entman M.L., Hartley C.J., Youker K.A., Zhu J., Hall S.R., Hawkins H.K., Berens K., Ballantyne C.M. Myocardial ischemia and reperfusion: a murine model. Am. J. Physiol. 1995, 269:H2147-H2154.
33. del Prete M.J., Vernal R., Dolznig H., Mullner E.W., Garcia-Sanz J.A. Isolation of polysome-bound mRNA from solid tissues amenable for RT-PCR and profiling experiments. RNA 2007, 13:414-421.
34. Han B., Zhang J.T. Regulation of gene expression by internal ribosome entry sites or cryptic promoters: the eIF4G story. Mol. Cell. Biol. 2002, 22:7372-7384.
35. Lal A., Mazan-Mamczarz K., Kawai T., Yang X., Martindale J.L., Gorospe M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 2004, 23:3092-3102.
36. Michael L.H., Ballantyne C.M., Zachariah J.P., Gould K.E., Pocius J.S., Taffet G.E., Hartley C.J., Pham T.T., Daniel S.L., Funk E., Entman M.L. Myocardial infarction and remodeling in mice: effect of reperfusion. Am. J. Physiol. 1999, 277:H660-H668.
37. Ashrafian H., Czibik G., Bellahcene M., Aksentijevic D., Smith A.C., Mitchell S.J., Dodd M.S., Kirwan J., Byrne J.J., Ludwig C., Isackson H., Yavari A., Stottrup N.B., Contractor H., Cahill T.J., Sahgal N., Ball D.R., Birkler R.I., Hargreaves I., Tennant D.A., Land J., Lygate C.A., Johannsen M., Kharbanda R.K., Neubauer S., Redwood C., de Cabo R., Ahmet I., Talan M., Gunther U.L., Robinson A.J., Viant M.R., Pollard P.J., Tyler D.J., Watkins H. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab. 2012, 15:361-371.
38. Lau A., Wang T., Whitman S., Zhang D. The predicted molecular weight of Nrf2: it is what it is not. Antioxid. Redox Signal. 2012, 10.1089/ars.2012.4754.
39. Nguyen T., Sherratt P.J., Pickett C.B. Regulatory mechanisms controlling gene expression mediated by the antioxidant response element. Annu. Rev. Pharmacol. Toxicol. 2003, 43:233-260.
40. Kwak M.K., Itoh K., Yamamoto M., Kensler T.W. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol. Cell. Biol. 2002, 22:2883-2892.
41. Zhang Y., Sano M., Shinmura K., Tamaki K., Katsumata Y., Matsuhashi T., Morizane S., Ito H., Hishiki T., Endo J., Zhou H., Yuasa S., Kaneda R., Suematsu M., Fukuda K. 4-Hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf2-dependent pathway. J. Mol. Cell. Cardiol. 2010, 49:576-586.
42. Stein A.B., Bolli R., Dawn B., Sanganalmath S.K., Zhu Y., Wang O.L., Guo Y., Motterlini R., Xuan Y.T. Carbon monoxide induces a late preconditioning-mimetic cardioprotective and antiapoptotic milieu in the myocardium. J. Mol. Cell. Cardiol. 2012, 52:228-236.
43. Deng C., Sun Z., Tong G., Yi W., Ma L., Zhao B., Cheng L., Zhang J., Cao F., Yi D. Alpha-lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. PLoS One 2013, 8:e58371.
44. Bai Y., Cui W., Xin Y., Miao X., Barati M.T., Zhang C., Chen Q., Tan Y., Cui T., Zheng Y., Cai L. Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J. Mol. Cell. Cardiol. 2013, 57:82-95.
45. Napoli C., Pinto A., Cirino G. Pharmacological modulation, preclinical studies, and new clinical features of myocardial ischemic preconditioning. Pharmacol. Ther. 2000, 88:311-331.
46. Clerk A., Cullingford T.E., Fuller S.J., Giraldo A., Markou T., Pikkarainen S., Sugden P.H. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J. Cell. Physiol. 2007, 212:311-322.
47. Downey J.M., Davis A.M., Cohen M.V. Signaling pathways in ischemic preconditioning. Heart Fail. Rev. 2007, 12:181-188.
48. Burgoyne J.R., Mongue-Din H., Eaton P., Shah A.M. Redox signaling in cardiac physiology and pathology. Circ. Res. 2012, 111:1091-1106.
49. Zhang X., Xiao Z., Yao J., Zhao G., Fa X., Niu J. Participation of protein kinase C in the activation of Nrf2 signaling by ischemic preconditioning in the isolated rabbit heart. Mol. Cell. Biochem. 2013, 372:169-179.
50. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H19-H27.
51. Otani H. Ischemic preconditioning: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2008, 10:207-247.
52. Yang X., Cohen M.V., Downey J.M. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc. Drugs Ther. 2010, 24:225-234.
53. Sanada S., Komuro I., Kitakaze M. Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H1723-H1741.
54. Ockaili R., Natarajan R., Salloum F., Fisher B.J., Jones D., Fowler A.A., Kukreja R.C. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H542-H548.
55. Dawn B., Bolli R. HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection?. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H522-H524.
56. Yet S.F., Tian R., Layne M.D., Wang Z.Y., Maemura K., Solovyeva M., Ith B., Melo L.G., Zhang L., Ingwall J.S., Dzau V.J., Lee M.E., Perrella M.A. Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice. Circ. Res. 2001, 89:168-173.
57. Hausenloy D.J., Ong S.B., Yellon D.M. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res. Cardiol. 2009, 104:189-202.
58. Wolin S.L., Cedervall T. The La protein. Annu. Rev. Biochem. 2002, 71:375-403.
59. Maraia R.J., Intine R.V. Recognition of nascent RNA by the human La antigen: conserved and divergent features of structure and function. Mol. Cell. Biol. 2001, 21:367-379.
60. Jacks A., Babon J., Kelly G., Manolaridis I., Cary P.D., Curry S., Conte M.R. Structure of the C-terminal domain of human La protein reveals a novel RNA recognition motif coupled to a helical nuclear retention element. Structure 2003, 11:833-843.
61. Costa-Mattioli M., Svitkin Y., Sonenberg N. La autoantigen is necessary for optimal function of the poliovirus and hepatitis C virus internal ribosome entry site in vivo and in vitro. Mol. Cell. Biol. 2004, 24:6861-6870.
62. Ali N., Pruijn G.J., Kenan D.J., Keene J.D., Siddiqui A. Human La antigen is required for the hepatitis C virus internal ribosome entry site-mediated translation. J. Biol. Chem. 2000, 275:27531-27540.